KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked ... in the Division of Oncology at Huntsman ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ... rates in different tumor types. Two inhibitors targeting the KRAS ...

Different Kirsten rat sarcoma virus (KRAS) mutations in ... treatment responses, with G12D and G12V mutations linked to worse outcomes compared with wild type. Researchers conducted a ...

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; ...

Adding immunotherapy to a new type of inhibitor that ... specifically targeting KRAS G12D, the form of the mutation more ...

Silexion Therapeutics (SLXN) announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi ...

The researchers found that KRAS-G12D, the most common mutation occurring ... only occur in pancreatic cancer and not in the other cancer types associated with KRAS mutations, such as lung cancer ...

It is important to note that the list is actively growing—in particular, the expansion of targetable KRAS variants, specifically KRAS G12D ... cancer. Amp, amplification; MSI-H, microsatellite ...

The researchers found that KRAS-G12D, the most common mutation occurring in 35% of ... a mutation that seems to only occur in pancreatic cancer and not in the other cancer types associated with KRAS ...

CHICAGO – Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ... rates in different tumor types. Two inhibitors targeting ...